Sequential afatinib and osimertinib in NSCLC patients

Written by Maximilian Hochmair

A recent publication from the Video Journal of Biomedicine summarizes an article originally published in Advances in Therapy entitled ‘Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib’.

The study was a post-hoc non-interventional, global, multicenter GioTag study, assessing sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) who had recieved the approved 40-mg starting dose of afatinib. The findings support the clinical benefit for sequential afatinib and osimertinib.

Original publication:

Nobuyuki Yamamoto, Takeshi Mera, Angela Märten & Maximilian J Hochmair. Observational study of sequential afatinib and osimertinib in EGFR mutation-positive NSCLC: patients treated with a 40-mg starting dose of afatinib. Adv. Ther. 37, 759–769 (2020) DOI: 10.1007/S12325-019-01187-y

About the Video Journal of Biomedicine:

The Video Journal of Biomedicine, published by Future Medicine, provides the missing link between high-quality research information and its intended audience, be that fellow experts, researchers in other fields, students and trainees, or the general public (including patients and caregivers). Through concise, high-quality videos, with the author on screen or via voice-over animation, researchers are able to personally explain their work, highlighting its importance, placing it in context, and discussing future implications.

Visit the Video Journal of Biomedicine to find out more>>

The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Oncology Central or Future Science Group.